English

BioStock: Evaxion and Pantherna reach preclinical proof-of-concept

Report this content

Evaxion Biotech has teamed up with Pantherna Therapeutics to test Evaxion’s AI-driven drug discovery technology in combination with an mRNA vaccine platform. The two biotech partners have announced preclinical proof-of-concept with their combined technologies, demonstrating promising anti-tumour effects.

Read the article at biostock.se:

Evaxion and Pantherna reach preclinical proof-of-concept - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Evaxion and Pantherna reach preclinical proof-of-concept
Tweet this